Role of linezolid in antimicrobial therapy;Papel de linezolid en terapéutica antimicrobiana

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 1, 2003, Pages 30-41

  Carmona, Pedro Manuel ^a   Romá, Eva ^a   Monte, Emilio ^a   García, Javier ^a   Gobernado, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antimicrobial chemotherapy; Gram positive resistance; Linezolid; Oxazolidinones

Indexed keywords

AMPHOTERICIN B; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORPROMAZINE; COTRIMOXAZOLE; DAPTOMYCIN; DIAZEPAM; DICLOXACILLIN; ERYTHROMYCIN; GLYCOPEPTIDE; KETOLIDE; LINEZOLID; METICILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENTAMIDINE; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; BONE MARROW SUPPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DYSPEPSIA; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INSOMNIA; KIDNEY FAILURE; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PANCREATITIS; PENICILLIN RESISTANCE; PRURITUS; PSEUDOMEMBRANOUS COLITIS; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THRUSH; VAGINA CANDIDIASIS; VOMITING;

EID: 12244267963     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042136     Document Type: Review

References (75)

1. Grupo de trabajo EPINE, Vaqué J, Roselló J. Evolución de la Prevalencia de las Infecciones Nosocomiales en los Hospitales Españoles - Proyecto EPINE 1990-1999. Madrid: Sociedad Española de Medicina Preventiva, Salud Pública e Higiene, 2001.
2. Waldogel FA. Staphylococcus aureus (including toxic shock syndrome). En: Mandell GL, Bennett JE, Dolin R, editors. Mandell Douglas Benneet's Principles and practice of infectious diseases, 4th ed. New York: Churchill-Livingstone, 1995; p. 1755-6.
3. García-Rodríguez JA, Muñoz Bellido JL. Epidemiología de la resistencia de grampositivos en España. Enferm Infecc Microbiol Clin 2002;1:1-7.
4. Grau S, Álvarez-Lerma F, Marín M, Gimeno JL. Problemática y soluciones actuales en el tratamiento de las infecciones por microorganismos grampositivos. Enferm Infecc Microbiol Clin 2001;19:393-8.
5. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneusly resistant to vancomycin. Lancet 1997;350:1670-3.
6. CDC Update. Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997. MMWR 1997;46:813-5.
7. Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: Clinical significance and treatment options. Drug 2001;61:1-7.
8. Tenover FC. Implications of vancomycin-resistant Staphylococcus aureus. J Hosp Infect 1999;43(Suppl):S3-7.
9. Cetinkaya Y, Falk P, Glen C. Vancomycin-Resistant Enterococci. Clin Microbiol Rev 2000;13:686-707.
10. Shinbarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of Action of Oxazolidinones: Effects of Linezolid and Eperezolid on Translation Reactions. Antimicrob Agents Chemother 1997;41:2132-6.
11. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria. Antimicrob Agents Chemother 1998;42:3251-5.
12. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-30.
13. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase negative Staphylococci, and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721-4.
14. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, Novel Oxazolidinone Antibacterial Agents. Antimicrob Agents Chemother 1996;40:839-45.
15. Jorgensen JH, Mcelmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother 1997;41:465-7.
16. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A, et al. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000;46:931-40.
17. Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid: A European inter-country comparison. J Antimicrob Chemother 2001;48:47-52.
18. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000;45:225-30.
19. Tubau F, Fernández-Roblas R, Liñares J, Martín R, Soriano F. In vitro activity of linezolid and 11 other antimicrobials against 566 isolates and comparison between NCCLS microdilution and Etest methods. J Antimicrob Chemother 2001;47:675-80.
20. Von Eiff C, Peters G. Comparative in vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999;43:569-73.
21. Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, Schmitz FJ. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, saprfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999;43:421-3.
22. Cercenado E, García-Garrote F, Bouza E. In vitro activity of Linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001;47:77-81.
23. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial patogens including vanxomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-62.
24. Gobernado M, Santos M. Estudio comparative de Linezolid con otros antimicrobianos. Rev Esp Quimioterap 2001;14(Supl 1):En prensa.
25. Hällgren A, Abednazari H, Ekdahl C, Hanberger H, Nilsson M, Samuelsson A, et al. Antimicrobial susceptibility patterns of entercocci in intensive care units in Sweden evaluated by different MIC breakpoint systems. J Antimicrob Chemother 2001;48:53-62.
26. Doern G, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison ofresistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
27. Betriu C, Redondo M, Palau ML, Sánchez A, Gómez M, Culebras E, et al. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin and trovafloxacin against erytromycin-susceptible and resistant streptococci. Antimicrob Agents Chemother 2000;44:1838-41.
28. Zaoutis T, Moore LS, Furness K, Klein JD. In vitro activities of linezolid, meropenem, and quinuprístin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates. Antimicrob Agents Chemother 2001; 45:1952-4.
29. Brown-Elliot BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 2001;45:1295-7.
30. Perry CM, Jarvis B. Linezolid: revisión de su uso en el tratamiento de las infecciones graves por grampositivos. Drugs 2001;61:525-52.
31. Goldstein EJC, Citron DM, Merina CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from sofa tissue bite infections in humans. Antimicrob Agents Chemother 1999;43:1469-74.
32. Livermore DM, Mushtaq S, Warner M. Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'. J Antimicrob Chemother 2001;48:452-4.
33. Munckhof WJ, Giles C, Turnidge JD. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria. J Antimicrob Chemother 2001;47:879-83.
34. Kaatz GW, Seo SM. In vitro activities or oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40:799-801.
35. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluorquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40:2428-30.
36. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000;47:797-802.
37. Zyvoxid Ficha Técnica para Europa. Pharmacia Spain 2001.
38. Base de Datos del Medicamento. Consejo General de Colegios Oficiales de Farmacéuticos. Madrid 2002. Consulta febrero 2002. Disponible en http://www.portalfarma.com/home.nsf
39. Linezolid. Drug Evaluation Monographs. DRUGDEX-System. Drug Information. Micromedex Computerized Clinical Information System. Englewood, Colorado 2002; Vol 111. Consultada febrero 2002. Disponible en: http://www.sefh.es/micromedex.htm.
40. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses. Antimicrob Agents Chemother 2001;45:1843-6.
41. Stevens DL, Smith LG, Bruss JB, McConnell-Martín A, Duvall SE, Todd WM, et al. Randomized Comparison of Linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-13.
42. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
43. Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Tauber MG. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000;46:981-5.
44. Villani P, Regazzi MB, Marubbi F, Viale P, Pagani L, Cristini F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46:936-7.
45. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: Case report and literature review. Scand J Infect Dis 2001;33:375-9.
46. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature. Clin Infect Dis 2001;33:477-82.
47. Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000;44:3438-40.
48. Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodyalisis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000;31:208-9.
49. Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:2304-8.
50. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, Dailey CF, Ford CW, Batts DH, et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 2001;47:349-52.
51. Patel R, Rouse MS, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001;45:621-3.
52. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000;30:146-51.
53. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373-5.
54. Valencia ME, Moreno V, Laguna F, González-Lahoz JM. Tuberculosis multirresistente por Mycobacterium bovis e infección por el virus de la inmunodeficiencia humana ¿Existen nuevas posibilidades terapéuticas? Enferm Infecc Microbiol Clin 2001;19:37-9.
55. Brown-Elliott B, Wallace RJ, Blinkhorn R, Crist CJ, Mann LB. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001;33:1433-4.
56. Cada DJ, Baker DE, Levien T. Linezolid. Hosp Pharm 2000;35:980-93.
57. Linezolid USP DI Drug Information for the Health Care Professional. Micromedex Computerized Clinical Information System. Englewood, Colorado 2002; Vol 111. Consultada febrero 2002. Disponible en: http://www.sefh.es/micromedex.htm.
58. García Sánchez JE, Fresnadillo Martínez MJ. Nuevos antibióticos activos frente a grampositivos. Rev Esp Quimioter 2000;13:344-51.
59. Anon. Linezolid (Zyvox). Med Lett Drug Ther 2000;42:45-6.
60. Physicians Desk Reference, 55th Ed. USA: Medical Economics Company, 2001.
61. Cupo-Abbott J. Linezolid: A synthetic oxazolidinone antimicrobial for treatment of serious Gram-positive infections. Formulary 2000;35:483-97.
62. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: An oxazolidinone antimicrobial agent. Clin Ther 2001;23:356-91.
63. American Health-System Pharmacists Society. Drug Information ASHP. Bethesda 2001.
64. Diekema DJ, Jones RN. Oxazolidinones. A review. Drug 2000;59:7-16.
65. Xiong YQ, Yeaman MR, Bayer AS. Linezolid: A new antibiotic. Drug of Today 2000;36:631-39.
66. Bain KT, Wittbrodt ET. Linezolid for the treatment ofresistant gram-positive cocci. Ann Pharmacother 2001;35:566-75.
67. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy 2001;21:1010-3.
68. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-8.
69. Waldrep TW, Skies DJ. Linezolid-Induced anemia and thrombocytopenia. Pharmacotherapy 2002;22:109-12.
70. Norrby R. Linezolid-A review of the first oxazolidinone. Expert Opin Pharmacother 2001;2:293-302.
71. UK Medicines Information Pharmacists Group. Linezolid. Evaluated information for the NHS, june 2001. Disponible en: http://www.ukdipg.org.uk/docs/linezolid.pdf.
72. Plouffe JF. Emerging Therapies for Serious Gram-positive Bacterial Infections: A Focus on Linezolid. Clin Infect Dis 2000;31(Supl 4):S144-9.
73. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosupression. JAMA 2001;285:1291.
74. Livermore DM. Quinupristin-dalfopristin and linezolid: Where, when, which and whether to use? J Antimicrob Chemother 2000;46:347-50.
75. Fagon JY, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-62.